Click Here to return To Results

 

Phase III Dose-Comparison Study of Glatiramer Acetate for Multiple Sclerosis Ann Neurol 69:75-82, Comi,G.,et al, 2011 See this aricle in Pubmed Article Abstract In relapsing-remitting MS patients, both the currently-approved GA 20mg and 40mg doses were safe and well-tolerated, with no gain in efficacy for the higher dose.

Related Tags

(click to filter results - removes previous filter) cop 1 efficacy multiple sclerosis multiple sclerosis,relapsing multiple sclerosis,treatment of safety tolerance

Click Here to return To Results